SCHEMBL4496033

SCHEMBL4496033

CCNC(=O)N(S)c1ccc2[nH]c(-c3ccccc3-c3nc4cc(NC(=O)N(S)CC)ccc4[nH]3)nc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.38
RXFP1 Q9HBX9 1/20 0.38
KDM4E B2RXH2 5/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
MAPT P10636 3/20 0.38
THRB P10828 1/20 0.38
LDLR P01130 1/20 0.37
NR2E3 Q9Y5X4 1/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HSD17B10 Q99714 2/20 0.36
ABL1 P00519 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
POLB P06746 2/20 0.36
HTT P42858 2/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4508672 0.81 NR2E3 (0.42) TP53RXFP1KDM4ENPC1RAB9A
SCHEMBL4483540 0.79 TP53 (0.40) TP53RXFP1KDM4ENPC1RAB9A
SCHEMBL4496027 0.74 KDM4E (0.65) TP53RXFP1KDM4ENPC1RAB9A
SCHEMBL4496122 0.73 KDM4E (0.61) TP53KDM4ENPC1RAB9AMAPT
SCHEMBL4496830 0.72 PTPRC (0.53) TP53RXFP1KDM4ENPC1RAB9A
SCHEMBL4480173 0.71 DGAT1 (0.60) TP53RXFP1KDM4ENPC1RAB9A
SCHEMBL17711232 0.68 F2 (0.55) TP53KDM4ENPC1RAB9AMAPT
SCHEMBL8351653 0.68 KDM4E (0.65) TP53KDM4ENPC1RAB9AMAPT
SCHEMBL4496201 0.68 TP53 (0.49) TP53RXFP1KDM4ENPC1RAB9A
SCHEMBL4496023 0.68 KDM4E (0.51) TP53RXFP1KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482373-B2 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2009-01-27 US disclosed
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2007-02-01 US disclosed
US-7132439-B2 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2006-11-07 US disclosed
US-20040029925-A1 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2004-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNA3, KCNB2 TP53 3963/4885RXFP1 4383/4885KDM4E 488/4885
US-20040029925-A1 Bis-benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNA3, KCNB2 TP53 3963/4885RXFP1 4383/4885KDM4E 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.